Results 181 to 190 of about 111,871 (303)

PARP Inhibitors in Lung Cancer [PDF]

Journal of Thoracic Oncology, 2012
openaire   +2 more sources

Management of Advanced Prostate Cancer in the Asia‐Pacific Region: Summary of the Asia‐Pacific Advanced Prostate Cancer Symposium 2025

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Summary of the Asia Pacific Advanced Prostate Cancer Symposium 2025, showing disciplines and diversity of participants, discussion topics (high‐risk localized/locally advanced prostate cancer; PSA persistence and recurrence; radioligand therapy; genetics and genomics; bone protection and other aspects of supportive care), key themes, and high‐level ...
Edmund Chiong, Renu Eapen, Nicholas Buchan, Kenneth Chen, Lukman Hakim, Agus Rizal Hamid, Jae‐Young Joung, Ravindran Kanesvaran, Makarand Khochikar, Jason Letran, Bannakij Lojanapiwat, Indranil Mallick, Chi Fai Ng, Pei Ing Ngam, Teng Aik Ong, Jacob Pang, Darren M. C. Poon, Natasha Roberts, Marniza Saad, Shinichi Sakamoto, Jeremy Tey, Sue Ping Thang, Poh Choo Toh, Levent Türkeri, Nguyễn Tuấn Vinh, Alvin Wong, Yao Zhu, ANZUP Cancer Trials Group, Ian D. Davis   +28 more
wiley   +1 more source

Characterization of exceptional responders with long-term PARP inhibitor therapy in recurrent ovarian cancer: an analysis of 23 patients from Charité. [PDF]

Arch Gynecol Obstet
Glajzer J, Sehouli J, Woopen H, Braicu EI, Baum J, Grabowski JP.   +5 more
europepmc   +1 more source

Inhibition of HMGA2 Leads to Reduced Cell Proliferation and Increased Apoptosis in Human Embryonal Carcinoma Cell Lines

Andrology, EarlyView.
ABSTRACT Background The most prevalent solid tumors in young men are testicular germ cell tumors (TGCTs), and embryonal carcinoma is the most common subtype among non‐seminomatous germ cell tumors (NSGCTs). Despite the excellent cure rates of cisplatin‐based chemotherapy, resistance develops in 15%–30% of patients with metastatic cancer, which results ...
Marco De Martino, Matteo Lampitto, Alfredo Fusco, Marco Barchi, Francesco Esposito, Paolo Chieffi   +5 more
wiley   +1 more source

Clinical approaches to overcome PARP inhibitor resistance. [PDF]

Mol Cancer
Zou Y, Zhang H, Chen P, Tang J, Yang S, Nicot C, Guan Z, Li X, Tang H.   +8 more
europepmc   +1 more source

Selective small molecule targeting of KDM4 as a therapeutic strategy to reduce proliferation of acute myeloid leukaemia

British Journal of Haematology, EarlyView.
Summary Acute myeloid leukaemia (AML) is an aggressive disease with poor survival and high relapse rates. Coupled with the complex mutational burden observed, there is an unmet clinical need for more targeted therapies. Epigenetic therapies have shown promise both as monotherapy and in combination strategies and specifically histone lysine demethylase,
Laura Monaghan, Roderick P. Bunschoten, Joana Bittencourt‐Silvestre, Taeju Park, Susan Gannon, Petrisor Alin Pirvan, Alex Hoose, Helen Wheadon, Robert M. J. Liskamp, Xu Huang, Heather G. Jørgensen   +10 more
wiley   +1 more source

Surgical Timing and Survival in Advanced High-Grade Serous Ovarian Cancer in the PARP Inhibitor Era. [PDF]

Cancers (Basel)
Kanno M, Fusegi A, Miyazaki N, Ozawa R, Netsu S, Aoki Y, Omi M, Nomura H, Yunokawa M, Kanao H.   +9 more
europepmc   +1 more source

Malignant craniopharyngiomas: Institutional experience and literature review

Brain Pathology, EarlyView.
We report the second case of malignant craniopharyngioma with BAP1 and TP53 mutations. A literature review identified 44 cases of malignant craniopharyngiomas with a median overall survival of 6 months. Eighteen (41%) occurred in patients without any history of radiation, suggesting that mechanisms other than radiation have contributed to their ...
Thomas J. Auen, Isabella W. Zhang, Weiwei Zhang, Jordan M. Burr, Matthew L. Carda, James L. Wisecarver, Nicole Shonka, Jesse L. Cox, Sahara J. Cathcart, Allison Cushman‐Vokoun, Jie Chen   +10 more
wiley   +1 more source

Quality of Life Measurement in PARP Inhibitor Trials of Epithelial Ovarian Cancer - What Do We Know? [PDF]

Cancer Control
Kumari S, Umadevi K, Sundeep D.
europepmc   +1 more source

The relationship between the cannabinoids and cardiac remodelling: A comprehensive review of pivotal mechanisms and emerging evidence

British Journal of Pharmacology, EarlyView.
Cardiac remodelling and fibrosis after myocardial infarction or during chronic diseases, such as arterial and pulmonary hypertension or diabetes mellitus, continue to be the more important prognostic factors in determining survival, and so the search for effective anti‐fibrotic interventions is an important target for research and therapy in cardiology.
Anna Krzyżewska, Marta Baranowska‐Kuczko, Hanna Kozłowska   +2 more
wiley   +1 more source